New shot aims to boost platelets in ITP patients

NCT ID NCT06880081

Recruiting now Disease control Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called PN20 in 12 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive a single injection of PN20, which is designed to stimulate platelet production. The main goal is to check safety and see if platelet counts improve within 28 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PN20 (thrombopoietin receptor agonist)
What this could lead to: If successful, this could point toward a new treatment option to raise platelet counts and reduce bleeding risk in people with ITP.
What could go wrong: This is a very early, small Phase 1b trial with only 12 participants, so results may not apply broadly. The main goal is safety, not proof of effectiveness, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura primary thrombocytopenia Purpura, Thrombocytopenic, Idiopathic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)

Contacts and locations

Locations

Affiliated Hospital of Guizhou Medical University
RECRUITING

Guiyang, Guizhou, 550004, China
Hematology Hospital of Chinese Academy of Medical Sciences
RECRUITING

Tianjin, Tianjin Municipality, 301609, China
Jining First People's Hospital
RECRUITING

Jining, Shandong, 272011, China
The Second Affiliated Hospital of Kunming Medical University
RECRUITING

Kunming, Yunnan, 650000, China
The Second Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.